Hematologist
CION Cancer Clinics
CAR-T cell therapy for childhood leukaemia in India | CION Cancer Clinics
CAR-T is available in India, but it is offered mainly to children and young people whose B-cell acute lymphoblastic leukaemia has come back or has not responded to standard chemotherapy. It is not a first treatment. This page explains who is considered, what the treatment involves, the reactions to watch for, and what to ask a CAR-T centre before you agree. At CION Cancer Clinics, our haematology team supports patients and families through treatment, cost questions and life at home.
BP
Medically reviewed by Dr. Basudev PokhrelConsultant Haematologist · last reviewed September 2026, next review due September 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- Is CAR-T available for children with leukaemia in India?
- Which children are considered for CAR-T, and which are not?
- What happens, step by step, if CAR-T goes ahead?
- What do the CAR-T terms on the paperwork mean?
- What do families often get wrong about CAR-T?
- What should you ask, and how can CION help?
- Common questions about CAR-T for childhood leukaemia
The short answer
Is CAR-T available for children with leukaemia in India?
Yes, CAR-T is now available in India, but only for a narrow group of children. It is usually offered for B-cell acute lymphoblastic leukaemia (B-ALL) that has come back after treatment, or that did not respond to standard chemotherapy. It is not a first treatment for a newly diagnosed child.
What CAR-T actually is
CAR-T uses your child's own T cells, a type of white blood cell that fights infection. The cells are collected from the blood, changed in a laboratory so they can recognise a marker called CD19 on the leukaemia cells, grown in large numbers and then given back through a drip. Once inside the body, they seek out and attack the leukaemia.
Where it is given
CAR-T is given only at a small number of specialist centres that have the laboratory links, intensive care and trained staff to manage its side effects. In India that includes a few large hospitals and some clinical trial programmes. A locally made CAR-T product has been approved in India, which has brought the cost well below imported options, though it remains a major expense.
CION does not make or give CAR-T. Our haematology team reviews your child's reports, discusses the case at a tumour board and helps you reach a qualified centre if CAR-T is a real option.Is my child eligible
Which children are considered for CAR-T, and which are not?
Eligibility is decided by the treating centre after a full review. These are the questions they usually ask first.
Usually considered
Children and young people whose B-ALL has relapsed, meaning it has come back, or whose leukaemia is refractory, meaning it did not go away with standard treatment.
Often also includes
- Relapse after a stem cell transplant
- Leukaemia still found on MRD testing after several courses
Usually not suitable
CAR-T is not used for a first diagnosis that is responding well to chemotherapy. It is not an option for AML, a different leukaemia, outside research studies.
Other reasons it may be ruled out
- The leukaemia cells no longer carry CD19
- A serious uncontrolled infection
- Heart, lung or kidney problems too severe for the side effects
Depends on the details
Leukaemia in the brain or spinal fluid, a very high leukaemia load, or earlier CAR-T treatment each need a specialist opinion. Some centres will proceed after extra treatment first. Others will not.
What this page cannot tell you
Whether your own child qualifies depends on reports only the treating team can read together: the marrow result, MRD, CD19 status, previous treatment and current health. Please do not rule CAR-T in or out from a general page.
Not sure whether this applies to you?
Ask an oncologistThe pathway
What happens, step by step, if CAR-T goes ahead?
-
Referral and assessment
The CAR-T centre reviews every report, repeats key tests and meets the family. Bring the full treatment history, including discharge summaries from other hospitals.
-
Collecting the T cells
Your child's blood is passed through a machine that separates out the T cells and returns the rest. This is called apheresis. Young children may need a central line for it.
-
Waiting while the cells are made
The cells are engineered and grown in a laboratory. During this wait many children receive bridging therapy, a milder treatment that keeps the leukaemia under control.
-
Preparing chemotherapy
A short course of chemotherapy lowers your child's own white cells so the CAR-T cells have room to grow.
-
The infusion
The cells go in through a drip, much like a blood transfusion. It is often quick. The close watching afterwards is the main part of the treatment.
-
Staying close to the centre
Families are asked to stay in hospital or nearby for several weeks, because the serious side effects usually appear in this early period. For families travelling from a Telangana or Andhra Pradesh district, plan accommodation early.
!
Signs that cannot wait after CAR-T
After going home, a fever, shivering, fast breathing, dizziness, unusual sleepiness, confusion, trouble speaking, shaking or a fit can be signs of a serious reaction. Call the CAR-T centre's emergency number straight away. If you cannot reach them, go to the nearest emergency department or call 108, and say your child has had CAR-T treatment. Do not wait to see if it settles.
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
Words you will hear
What do the CAR-T terms on the paperwork mean?
- CD19
- A marker on the surface of B cells and most B-ALL cells. The CAR-T cells are built to find it.
- Cytokine release syndrome (CRS)
- A strong immune reaction as the CAR-T cells work. It can cause high fever and low blood pressure, and is treated by the centre's team.
- ICANS
- Effects on the brain and nerves, such as confusion, trouble with words or fits. It is usually temporary but needs close watching.
- B-cell aplasia
- The CAR-T cells also remove healthy B cells, so your child makes fewer antibodies. Some children need regular antibody top-ups.
- Bridging therapy
- Treatment given while the CAR-T cells are being made, to keep the leukaemia in check.
Commonly believed
What do families often get wrong about CAR-T?
"CAR-T is a new treatment, so it must be better
than chemotherapy."
For most newly diagnosed children, standard chemotherapy works well and remains the right first treatment. CAR-T is kept for leukaemia that has come back or not responded. Asking for it early does not give your child an advantage.
"Once CAR-T works, the leukaemia is gone for
good."
Many children reach remission, meaning no leukaemia can be found on tests. Some later relapse, and some centres plan a stem cell transplant afterwards. Regular follow-up tests continue for a long time.
"It is just one drip, so it must be gentle."
The infusion itself is simple. The reactions that follow can be serious and sometimes need intensive care. That is why it is given only at centres equipped for it.
"We have to go abroad for CAR-T."
Not necessarily. CAR-T is now given at some centres in India, including through clinical trials. Ask your haematologist which options fit your child before planning travel overseas.
Before you agree
What should you ask, and how can CION help?
Ask the CAR-T centre the same questions you would ask about any major treatment. You are entitled to clear answers, in writing if you want them, before you sign consent.
Questions for the treating centre
How many children with B-ALL has the centre treated with CAR-T? Is the product approved, or is it part of a trial? What happens if the cells cannot be made in time? Does the centre have a paediatric intensive care unit on site? Is a stem cell transplant planned afterwards? How long must we stay nearby, and who do we call at night after discharge?
Cost and support schemes
The total cost covers far more than the cells: tests, collection, bridging therapy, hospital stay, intensive care if needed and months of follow-up. Ask for a written, itemised estimate. Check whether your insurance, CGHS, ECHS, EHS, Aarogyasri or PM-JAY covers any part, as scheme rules change. Some trials and charities help with costs.
Where CION fits in
Our haematology team can go through your child's reports with you, explain whether CAR-T is worth asking about, present the case at a tumour board and coordinate the referral. We can also support care closer to home before and after treatment.
This page is general information. It cannot tell you how your child will respond. Only the treating team can discuss that with your child's reports in front of them.Questions we are asked
Common questions about CAR-T for childhood leukaemia
Can CAR-T be the first treatment for my child's leukaemia?
Usually not. For a newly diagnosed child with ALL, standard chemotherapy in phases is the recommended first treatment and works well for most children. CAR-T is kept for leukaemia that comes back or does not respond. Your haematologist will tell you if your child's situation changes and CAR-T becomes worth discussing.
Does CAR-T work for AML in children?
The approved CAR-T products are for B-cell leukaemia and lymphoma. They target CD19, which AML cells do not usually carry. CAR-T for AML is still being studied in research trials. If your child has AML, ask the haematologist about the options that are established for that disease.
Will my child need a stem cell transplant after CAR-T?
Sometimes. Some centres plan a transplant after CAR-T to lower the chance of relapse, especially when a matched donor is available. Others watch closely and keep transplant for later if needed. The decision depends on your child's history and test results, so ask the centre what their plan is before you start.
How long will we have to stay near the hospital?
Most centres ask families to stay in hospital or very close by for several weeks after the infusion. This is when the serious reactions are most likely. The exact period differs between centres and products, so ask for it in writing and plan travel, accommodation and time off work around it.
Is CAR-T in India cheaper than going abroad?
Generally yes. The Indian-made product costs far less than imported CAR-T, and there is no overseas travel or long stay abroad. It is still one of the most expensive treatments available. Ask for an itemised written estimate, and check insurance and government schemes, whose rules change over time.
What if the cells cannot be made?
Occasionally the laboratory cannot grow enough cells, often because earlier treatment has left few healthy T cells. The centre may try collecting again or suggest another treatment. Ask in advance what happens in that case and whether any payment already made is refunded or carried forward.
Does my child need to avoid school or other children afterwards?
For some months, yes. The immune system is weak after CAR-T, and infections can be serious. The team will tell you when school, crowds and vaccines are safe again. Keep the centre's contact card with you, and tell any local doctor that your child has had CAR-T.
Can CION tell us whether CAR-T is right for our child?
We can review the reports, explain what they mean in plain language and discuss the case at a tumour board. If CAR-T looks worth pursuing, we help you reach a qualified centre and ask the right questions. The final eligibility decision is made by the centre that gives the treatment.
Your Haematologist
Meet CION's haematologist. One specialist for your blood report and your plan.
Dr. Basudev Pokhrel reviews blood counts, transfusion needs and blood disorders, and works with the CION tumour board on blood cancers.
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- National Cancer Institute — CAR T Cells: Engineering Patients' Immune Cells to Treat Their Cancers
- Cancer Research UK — CAR T-cell therapy
- Leukemia & Lymphoma Society — Chimeric Antigen Receptor (CAR) T-Cell Therapy
- Cancer.Net — What is CAR T-cell therapy?
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
Childhood acute lymphoblastic leukaemiaThe full guide to ALL in childrenRelapsed Childhood LeukaemiaAll the options when leukaemia comes backMRD in Childhood LeukaemiaThe test that often shapes the CAR-T decisionChildhood Blood Cancer Treatment Cost in IndiaWhat treatment costs and which schemes helpImmunotherapy guideHow immune-based treatments work
Talk to us
Told CAR-T might be an option?
Share your child's reports with us. Our haematology team will explain them, discuss the case at a tumour board and help you reach a qualified centre.